Latest Humira biosimilar settlement provides further proof of AbbVie patent strategy’s effectiveness 16 Apr 18
With the recent announcement that it had reached a settlement in its patent dispute with Samsung Bioepis, AbbVie has scored another significant victory in efforts to delay market entry to biosimilar versions of its drug, Humira. While allowing Samsung to launch its product in European jurisdictions later this year, the deal keeps the copycat arthritis treatment out of the lucrative US market until 2023.
Want to read more?
Register to access two of our subscriber-only articles per month
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts
What our customers are saying
Being a charter subscriber of IAM, I have found useful articles in every issue from the beginning. I like the variety in the subject matter and the depth at which most articles explore. Your ability to attract the best practitioners of IAM to submit articles keeps the quality and usefulness of your publication at a consistently high level.
ipCapital Group (ipCG)
Subscribe to receive access to the full range of premium business intelligence, insights and analysis, as well as our IP directories, guides and daily news.
Register for more free content
- Read more IAM blogs and articles
- Receive the editor's weekly review by email